iBio, Inc. (IBIO)
NASDAQ: IBIO · Real-Time Price · USD
1.370
-0.010 (-0.72%)
At close: Jul 20, 2026, 4:00 PM EDT
1.400
+0.030 (2.19%)
Pre-market: Jul 21, 2026, 8:08 AM EDT
iBio, Inc. Employees
iBio, Inc. had 20 employees as of June 30, 2025. The number of employees increased by 4 or 25.00% compared to the previous year.
Employees
20
Change (1Y)
4
Growth (1Y)
25.00%
Revenue / Employee
$15,000
Profits / Employee
-$1,380,300
Market Cap
68.06M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 20 | 4 | 25.00% | 20 | 0 |
| Jun 30, 2024 | 16 | -10 | -38.46% | 16 | 0 |
| Jun 30, 2023 | 26 | -80 | -75.47% | 26 | 0 |
| Jun 30, 2022 | 106 | 31 | 41.33% | 105 | 1 |
| Jun 30, 2021 | 75 | 24 | 47.06% | 49 | 26 |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| XBiotech | 87 |
| PMV Pharmaceuticals | 54 |
| Pliant Therapeutics | 49 |
| Enlivex | 34 |
| Gain Therapeutics | 21 |
| LeonaBio | 19 |
| ImageneBio | 17 |
| Annovis Bio | 7 |
IBIO News
- 20 days ago - iBio announces new preclinical data from IBIO-610 study - TheFly
- 20 days ago - iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study - GlobeNewsWire
- 6 weeks ago - iBio initiated with an Outperform at Raymond James - TheFly
- 6 weeks ago - iBio, Inc. Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - iBio to Participate in Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 7 weeks ago - iBio doses first participant in IBIO-600 trial - TheFly
- 7 weeks ago - iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity - GlobeNewsWire
- 2 months ago - iBio, Inc. Slides: Corporate presentation - Filings